What is Controlant?
Controlant operates as a global leader in the digital transformation of pharmaceutical supply chains. By leveraging real-time visibility, automation, and data-driven insights, the company addresses the critical need for integrity and efficiency in the transport of temperature-sensitive medical products. Their core mission centers on the elimination of waste within the supply chain, a goal achieved through the deployment of sophisticated IoT-enabled monitoring solutions. This approach not only safeguards the efficacy of life-saving pharmaceuticals but also aligns with broader corporate sustainability mandates, positioning Controlant as an essential partner for global healthcare organizations seeking to optimize their logistics infrastructure through digital innovation.
How much funding has Controlant raised?
Controlant has raised a total of $17.5M across 2 funding rounds:
Unspecified
$2.5M
Series B
$15M
Unspecified (2016): $2.5M with participation from Frumtak Investment Fund
Series B (2020): $15M, investors not publicly disclosed
Key Investors in Controlant
Frumtak Investment Fund
Frumtak Ventures is an early-stage venture capital fund based in Iceland that invests in local innovation with global potential. The firm focuses on supporting founders who have shown early traction and the capability for international growth.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Controlant?
With the recent influx of capital, Controlant is well-positioned to accelerate its expansion into new international markets and further refine its proprietary technology stack. The company is expected to prioritize the scaling of its automated monitoring platforms, which are increasingly vital for the secure distribution of vaccines and biologics. By focusing on the intersection of sustainability and supply chain resilience, Controlant aims to set new industry standards for zero-waste logistics. Future strategic initiatives will likely involve deepening partnerships with global pharmaceutical distributors and enhancing the predictive analytics capabilities of their platform to preemptively mitigate risks in the cold chain, thereby ensuring long-term operational excellence and market leadership.
See full Controlant company page
